Compared with the baseline, Belimumab group reduced significantly SLEDAI-2K and BILAG scores (Figure 2B) of SLE patients, and low complement (C3 and/or C4, < lower limit of normal) or high ESR demonstrated an improvement (Figure 2E). This evidence concerns the gene C3 and systemic lupus erythematosus.